Bone Biologics Corp
BBLG
Company Profile
Business description
Bone Biologics Corp is a healthcare solutions provider based in the United States. As a biotechnology firm, it engages its efforts in developing therapeutics to aid bone regeneration. The company's portfolio comprises its lead product, NELL-1, which is a bone void filler. Bone Biologics' technology has applications in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine.
Contact
2 Burlington Woods Drive
Suite 100
BurlingtonMA01803
USAT: +1 781 552-4452
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
2
Stocks News & Analysis
stocks
Meta earnings: Strong end to 2025 as AI monetization begins to show
Investors please with latest results.
stocks
Why doesn’t the market like the earnings from this US tech giant?
Good quarter with AI demand ramping.
stocks
Our Tesla fair value increases meaningfully
Progress on Robotaxi and Optimus shows real world AI growth.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,164.80 | 94.40 | -1.02% |
| CAC 40 | 8,078.84 | 7.48 | 0.09% |
| DAX 40 | 24,398.10 | 88.64 | 0.36% |
| Dow JONES (US) | 49,071.56 | 55.96 | 0.11% |
| FTSE 100 | 10,159.36 | 12.40 | -0.12% |
| HKSE | 27,390.46 | 577.63 | -2.07% |
| NASDAQ | 23,685.12 | 172.33 | -0.72% |
| Nikkei 225 | 53,322.85 | 52.75 | -0.10% |
| NZX 50 Index | 13,423.18 | 74.57 | 0.56% |
| S&P 500 | 6,969.01 | 9.02 | -0.13% |
| S&P/ASX 200 | 8,869.10 | 86.00 | -0.96% |
| SSE Composite Index | 4,117.95 | 40.04 | -0.96% |